Supernus Pharmaceuticals, Inc. (0LB2.L)
USD 33.23
(3.01%)
USD 33.23
(3.01%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 98.26 Million USD | -34.46% |
| 2022 | 153.44 Million USD | 24.88% |
| 2021 | 129.18 Million USD | -42.83% |
| 2020 | 212.4 Million USD | 23.39% |
| 2019 | 180.41 Million USD | 7.52% |
| 2018 | 151.5 Million USD | 54.57% |
| 2017 | 107.67 Million USD | 83.91% |
| 2016 | 56.61 Million USD | 203.52% |
| 2015 | 21.76 Million USD | -25.47% |
| 2014 | -4.35 Million USD | 140.01% |
| 2013 | -83.68 Million USD | -44.04% |
| 2012 | -41.83 Million USD | -16.29% |
| 2011 | -36.72 Million USD | 4.08% |
| 2010 | -38.28 Million USD | -834.86% |
| 2009 | 5.21 Million USD | 121.99% |
| 2008 | -23.68 Million USD | -44.96% |
| 2007 | -16.34 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 40.84 Million USD | 67.08% |
| 2024 Q2 | 38.92 Million USD | 135.88% |
| 2024 Q1 | 16.5 Million USD | -59.42% |
| 2023 Q4 | 40.66 Million USD | 29.96% |
| 2023 Q3 | 31.29 Million USD | 490.6% |
| 2023 Q1 | 28.84 Million USD | -47.59% |
| 2023 Q2 | 5.29 Million USD | -81.63% |
| 2023 FY | - USD | -34.46% |
| 2022 FY | - USD | 24.88% |
| 2022 Q4 | 55.02 Million USD | 145.55% |
| 2022 Q2 | 35.43 Million USD | -6.69% |
| 2022 Q1 | 37.97 Million USD | 79.72% |
| 2022 Q3 | 22.41 Million USD | -36.76% |
| 2021 Q3 | 40.97 Million USD | 20.87% |
| 2021 Q1 | 24.05 Million USD | -54.94% |
| 2021 FY | - USD | -42.83% |
| 2021 Q2 | 33.9 Million USD | 40.94% |
| 2021 Q4 | 21.13 Million USD | -48.43% |
| 2020 Q3 | 64.9 Million USD | 15.21% |
| 2020 Q2 | 56.33 Million USD | 61.94% |
| 2020 Q1 | 34.78 Million USD | -25.64% |
| 2020 FY | - USD | 23.39% |
| 2020 Q4 | 53.37 Million USD | -17.76% |
| 2019 Q1 | 25.42 Million USD | -42.69% |
| 2019 Q3 | 39.72 Million USD | -6.74% |
| 2019 Q2 | 42.59 Million USD | 67.52% |
| 2019 Q4 | 46.78 Million USD | 17.75% |
| 2019 FY | - USD | 7.52% |
| 2018 FY | - USD | 54.57% |
| 2018 Q1 | 32.6 Million USD | -7.44% |
| 2018 Q2 | 39.38 Million USD | 20.81% |
| 2018 Q3 | 41.93 Million USD | 6.48% |
| 2018 Q4 | 44.36 Million USD | 5.8% |
| 2017 Q1 | 18.06 Million USD | 8.2% |
| 2017 Q3 | 23.15 Million USD | -13.35% |
| 2017 Q4 | 35.22 Million USD | 52.1% |
| 2017 FY | - USD | 83.91% |
| 2017 Q2 | 26.72 Million USD | 47.97% |
| 2016 Q3 | 20.82 Million USD | 92.76% |
| 2016 Q2 | 10.8 Million USD | 91.41% |
| 2016 Q1 | 5.64 Million USD | -20.29% |
| 2016 FY | - USD | 203.52% |
| 2016 Q4 | 16.69 Million USD | -19.86% |
| 2015 Q2 | 3.23 Million USD | -13.81% |
| 2015 Q3 | 4.48 Million USD | 38.45% |
| 2015 Q4 | 7.08 Million USD | 57.97% |
| 2015 FY | - USD | -25.47% |
| 2015 Q1 | 3.75 Million USD | -22.52% |
| 2014 Q4 | 4.84 Million USD | -83.56% |
| 2014 Q3 | 29.48 Million USD | 623.81% |
| 2014 Q2 | 4.07 Million USD | 131.12% |
| 2014 FY | - USD | 140.01% |
| 2014 Q1 | -13.09 Million USD | -16.39% |
| 2013 Q1 | -17.68 Million USD | -39.18% |
| 2013 Q3 | -16.87 Million USD | -9.34% |
| 2013 Q4 | -11.24 Million USD | 33.33% |
| 2013 FY | - USD | -44.04% |
| 2013 Q2 | -15.43 Million USD | 12.75% |
| 2012 Q2 | -9.39 Million USD | -16.17% |
| 2012 Q4 | -12.7 Million USD | -8.37% |
| 2012 FY | - USD | -16.29% |
| 2012 Q3 | -11.72 Million USD | -24.78% |
| 2012 Q1 | -8.09 Million USD | 59.17% |
| 2011 Q3 | -9.95 Million USD | -22.55% |
| 2011 Q4 | -19.81 Million USD | -99.12% |
| 2011 FY | - USD | 4.08% |
| 2011 Q2 | -8.12 Million USD | 11.23% |
| 2011 Q1 | -9.14 Million USD | 52.15% |
| 2010 FY | - USD | -834.86% |
| 2010 Q4 | -19.11 Million USD | 0.0% |
| 2009 FY | - USD | 121.99% |
| 2009 Q4 | -13.43 Million USD | 0.0% |
| 2008 FY | - USD | -44.96% |
| 2007 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| uniQure N.V. | -253.1 Million USD | 138.823% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 294.301% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 211.68% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 128.443% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 136.941% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 183.521% |
| Imunon, Inc. | -20.78 Million USD | 572.816% |
| Dynavax Technologies Corporation | 9.66 Million USD | -916.574% |
| Editas Medicine, Inc. | -163.11 Million USD | 160.24% |
| FibroGen, Inc. | -261.4 Million USD | 137.59% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 121.884% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 372.33% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 76.385% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 122.373% |
| Verastem, Inc. | -83.16 Million USD | 218.152% |
| Zoetis Inc. | 3.68 Billion USD | 97.333% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 97.866% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 212.393% |
| Homology Medicines, Inc. | -47.75 Million USD | 305.758% |
| Nektar Therapeutics | -243.1 Million USD | 140.419% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 197.456% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 363.557% |
| Perrigo Company plc | 646.2 Million USD | 84.794% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 165.461% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 100.871% |
| Illumina, Inc. | -608 Million USD | 116.162% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 99.09% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 96.982% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 194.672% |
| Waters Corporation | 1.02 Billion USD | 90.388% |
| Biogen Inc. | 2.37 Billion USD | 95.866% |
| Evolus, Inc. | -41.81 Million USD | 335.02% |
| Adicet Bio, Inc. | -136.53 Million USD | 171.968% |
| bluebird bio, Inc. | -167.16 Million USD | 158.783% |
| Geron Corporation | -174.78 Million USD | 156.22% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 143.075% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 206.715% |
| Myriad Genetics, Inc. | -67.8 Million USD | 244.929% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 119.407% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 91.559% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 321.128% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 68.332% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 97.889% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 94.141% |
| OPKO Health, Inc. | -65.51 Million USD | 249.982% |
| Exelixis, Inc. | 196.6 Million USD | 50.02% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 9.289% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 276.236% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 143.674% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 142.721% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 78.258% |
| Blueprint Medicines Corporation | -474.61 Million USD | 120.704% |
| Insmed Incorporated | -654.73 Million USD | 115.008% |
| TG Therapeutics, Inc. | 26.1 Million USD | -276.483% |
| Incyte Corporation | 919.42 Million USD | 89.313% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 119.446% |